ArticleFrontiers in oncology2021

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient.

Junyi Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.